Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $216,257.40 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the completion of the sale, the chief operating officer now owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Blueprint Medicines Stock Up 1.3 %

BPMC stock traded up $1.24 during mid-day trading on Monday, reaching $97.62. The company had a trading volume of 542,247 shares, compared to its average volume of 690,484. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The company has a market capitalization of $6.20 billion, a price-to-earnings ratio of -45.68 and a beta of 0.59. The firm has a fifty day simple moving average of $90.97 and a 200 day simple moving average of $98.04. Blueprint Medicines Co. has a fifty-two week low of $70.39 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same quarter last year, the company earned ($2.20) EPS. Blueprint Medicines’s revenue for the quarter was up 126.5% compared to the same quarter last year. Analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BPMC. Triad Wealth Partners LLC purchased a new position in Blueprint Medicines during the 2nd quarter worth approximately $27,000. Quarry LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter valued at approximately $32,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter valued at approximately $108,000. Finally, CWM LLC grew its stake in shares of Blueprint Medicines by 114.6% in the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 590 shares during the last quarter.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several analyst reports. UBS Group initiated coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. Wells Fargo & Company dropped their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. JPMorgan Chase & Co. assumed coverage on Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price target for the company. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.